Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
Doria C , Leali PT , Solla F , Maestretti G , Balsano M , Scarpa RM 
Clin Cases Miner Bone Metab.2016 Sep-Dec ; 13(3):195-199.
PubMedで表示
Google翻訳で開く
(151view , 0users)
Full Text Sources
Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone.
PMID: 28228781 [PubMed - in process]
PMID: 28228781 [PubMed - in process]
関連論文
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
- [Review] Clinical utility of denosumab for treatment of bone loss in men and women.
- Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
- Treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients. A prospective randomized multicenter international study with Denosumab Vs Alendronate.